| scholarly article | Q13442814 |
| P356 | DOI | 10.1182/BLOOD-2008-03-143735 |
| P698 | PubMed publication ID | 18497321 |
| P50 | author | Massimo Bernardi | Q102058896 |
| P2093 | author name string | Andrea Bacigalupo | |
| Alessandro Rambaldi | |||
| Francesco Onida | |||
| Luca Malcovati | |||
| Renato Fanin | |||
| Cristiana Pascutto | |||
| Raffaella Cerretti | |||
| Alberto Bosi | |||
| Maria Teresa Van Lint | |||
| Rosi Oneto | |||
| Emilio Paolo Alessandrino | |||
| Anna Paola Iori | |||
| Matteo Giovanni Della Porta | |||
| Paola Marenco | |||
| Pietro Pioltelli | |||
| Michele Falda | |||
| Gruppo Italiano Trapianto di Midollo Osseo (GITMO) | |||
| P433 | issue | 3 | |
| P921 | main subject | myelodysplastic syndrome | Q954625 |
| P1104 | number of pages | 8 | |
| P304 | page(s) | 895-902 | |
| P577 | publication date | 2008-05-22 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) | |
| P478 | volume | 112 |
| Q36431041 | Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how? |
| Q36811828 | Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: the past decade |
| Q26824434 | Allogeneic hematopoietic cell transplantation for myelodysplastic syndromes: lingering uncertainties and emerging possibilities |
| Q36029093 | Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine |
| Q39092515 | Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel |
| Q43164242 | Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program |
| Q41031192 | Causes of mortality after haploidentical hematopoietic stem cell transplantation and the comparison with HLA-identical sibling hematopoietic stem cell transplantation |
| Q38442976 | Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. |
| Q43202931 | Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group |
| Q36063049 | Current status of allogeneic hematopoietic cell transplantation for MDS. |
| Q34013796 | Current therapy of myelodysplastic syndromes |
| Q48101262 | Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System |
| Q48733699 | Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome |
| Q84707051 | Early detection of relapse in patients with myelodysplastic syndrome after allo-SCT |
| Q36339459 | Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. |
| Q37889846 | Flow cytometry immunophenotyping for the evaluation of bone marrow dysplasia |
| Q33767314 | Hematopoietic stem cell transplantation for MDS. |
| Q37738524 | High-risk myelodysplastic syndromes: chemotherapy, transplantation, and beyond |
| Q97645639 | Immune checkpoints bone marrow expression as the predictor of clinical outcome in myelodysplastic syndrome |
| Q37146038 | Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome |
| Q34272525 | Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a [...] |
| Q35265820 | Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS) |
| Q35146316 | Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplasti |
| Q42879186 | Iron overload in hematologic malignancies and outcome of allogeneic hematopoietic stem cell transplantation |
| Q37622925 | Iron overload, hematopoietic cell transplantation, and graft-versus-host disease |
| Q46264493 | Labile plasma iron levels predict survival in patients with lower-risk Myelodysplastic syndromes. |
| Q37730013 | Long-term follow-up after allogeneic stem cell transplantation in patients with myelodysplastic syndromes or secondary acute myeloid leukemia: a single center experience |
| Q28082460 | MDS prognostic scoring systems – past, present, and future |
| Q38220788 | Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes |
| Q36683757 | Monosomal karyotype at the time of diagnosis or transplantation predicts outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic syndrome |
| Q43451303 | Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia |
| Q36133023 | Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study |
| Q33847018 | Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes |
| Q82686483 | Myelodysplastic syndromes |
| Q42586754 | Myelodysplastic syndromes with bone marrow fibrosis |
| Q36416338 | Myelodysplastic syndromes, version 2.2015 |
| Q37723847 | Myelodysplastic syndromes: clinical practice guidelines in oncology |
| Q33393647 | NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes |
| Q37076932 | Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome |
| Q37833060 | Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments |
| Q28084813 | Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia |
| Q42588904 | Outcome of allogeneic stem cell transplantation following reduced-intensity conditioninig regimen in patients with idiopathic myelofibrosis: the g.I.T.m.o. Experience |
| Q36166896 | Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients |
| Q36544315 | Pre-transplant weight loss predicts inferior outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndrome |
| Q33707461 | Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study |
| Q37810120 | Prognostic molecular markers in myelodysplastic syndromes |
| Q36920394 | Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and M |
| Q34612644 | Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome |
| Q34549306 | Role and timing of hematopoietic cell transplantation for myelodysplastic syndrome |
| Q27010653 | Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy |
| Q37404489 | The evolution of hematopoietic SCT in myelodysplastic syndrome |
| Q34386812 | The search for better prognostic models in myelodysplastic syndromes |
| Q34049017 | There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes |
| Q37000193 | Three-component cure rate model for nonproportional hazards alternative in the design of randomized clinical trials |
| Q35854094 | Transplantation for myelodysplastic syndrome in the era of hypomethylating agents |
| Q45756342 | Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party. |
| Q38148983 | When to transplant MDS, and what to do when transplant fails |
| Q35096163 | Wherefrom and whereabouts of an alien: the American liver fluke Fascioloides magna in Austria: an overview |
| Q86941724 | [Retrospective efficacy analysis of decitabine bridging allogeneic hematopoietic stem cell transplantation on the treatment of myelodysplastic syndrome] |
Search more.